DMEMEDS shared post via Reuters: Britain's cost agency not ready to back Gilead hepatitis C drug

LONDON (Reuters) - Britain's healthcare cost-effectiveness watchdog said on Monday it needed more information about Gilead Sciences' pricey new hepatitis C drug Sovaldi before deciding if it should be used on the state health service. [Category: healthNews] http://feeds.reuters.com/~r/reuters/healthNews/~3/rNcPWKYoYWc/story01.htm

Read More